We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
- Authors
Ko, Andrew H; Dito, Elizabeth; Schillinger, Brian; Venook, Alan P; Bergsland, Emily K; Tempero, Margaret A
- Abstract
No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line treatment with a gemcitabine-based regimen. There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced pancreatic cancer. We, therefore, evaluated this regimen in patients with gemcitabine-refractory disease.
- Publication
Cancer investigation, 2008, Vol 26, Issue 1, p47
- ISSN
1532-4192
- Publication type
Journal Article
- DOI
10.1080/07357900701681483